Produces and sells ethanol in California. Captures biogas from dairy operations and converts it into renewable natural gas. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 0.7× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 2% of them.
Analysts' average target sits 13% below today's price.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are going backwards, not just slowing.
An investor who bought at the very peak is down 91% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 12 months, company executives reported 20 buys and 16 sells. Management buying with its own money is usually read as a good sign.
A loss of $77.0M against $208.0M in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
The stock trades 13% above the average analyst price target.
On our five-subject report card, AMTX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: AMTX’s sales are going backwards, and it closed last year at a loss. The road back runs through both.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.